▶Nevirapineis predicted to decrease the exposure to
glecaprevir. Avoid.rStudy
▶Nevirapineis predicted to markedly decrease the exposure to
grazoprevir. Avoid.rStudy
▶Nevirapineis predicted to decrease the concentration of
guanfacine. Adjust dose.oTheoretical
▶Nevirapinedecreases the exposure toHIV-protease inhibitors.
Refer to specialist literature.oStudy
▶Nevirapineis predicted to decrease the effects ofhormone
replacement therapy.oAnecdotal
▶Nevirapineis predicted to decrease the exposure toidelalisib.
Avoid.oTheoretical
▶Nevirapineis predicted to decrease the exposure toimatinib.
oStudy
▶Nevirapineis predicted to decrease the exposure toivacaftor.
rTheoretical
▶Nevirapineis predicted to decrease the exposure tolapatinib.
Avoid.rStudy
▶Nevirapineis predicted to decrease the efficacy of
levonorgestrel. For FSRH guidance, seeContraceptives,
interactionsp. 497.rTheoretical
▶Nevirapineis predicted to decrease the exposure tolurasidone.
Monitor and adjust dose.oTheoretical
▶Nevirapinedecreases the exposure tomacrolides
(clarithromycin).oStudy
▶Nevirapinedecreases the concentration ofmidazolam. Monitor
and adjust dose.oStudy
▶Nevirapineis predicted to decrease the exposure tonetupitant.
oTheoretical
▶Nevirapineis predicted to decrease the exposure tonilotinib.
Avoid.rTheoretical
▶Nevirapineis predicted to decrease the efficacy of
norethisterone. For FSRH guidance, seeContraceptives,
interactionsp. 497.rAnecdotal
▶Nevirapineis predicted to decrease the exposure toolaparib.
Avoid.oTheoretical
▶Nevirapinedecreases the exposure toopioids(methadone).
Monitor and adjust dose.rStudy
▶Nevirapineis predicted to decrease the exposure to
osimertinib.rTheoretical
▶Nevirapineis predicted to decrease the exposure to
paritaprevir(with ritonavir and ombitasvir). Avoid.r
Study
▶Nevirapineis predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors.oTheoretical
▶Nevirapineis predicted to decrease the exposure to
pibrentasvir. Avoid.rStudy
▶Nevirapineis predicted to decrease the exposure toquetiapine.
oStudy
▶Nevirapineis predicted to decrease the exposure toribociclib.
oStudy
▶Rifampicindecreases the concentration ofnevirapine. Avoid.
rStudy
▶Nevirapineis predicted to decrease the exposure torilpivirine.
Avoid.rTheoretical
▶Nevirapineis predicted to decrease the exposure torolapitant.
Avoid.rStudy
▶Nevirapineis predicted to decrease the exposure toruxolitinib.
Monitor and adjust dose.oTheoretical
▶Nevirapineis predicted to decrease the exposure tosimeprevir.
Avoid.rStudy
▶Nevirapineis predicted to decrease the concentration of
sirolimus. Monitor and adjust dose.oTheoretical
▶St John’s Wortis predicted to decrease the concentration of
nevirapine. Avoid.rTheoretical
▶Nevirapineslightly decreases the exposure tostatins
(atorvastatin).nStudy
▶Nevirapinemoderately decreases the exposure tostatins
(simvastatin).oStudy
▶Nevirapineis predicted to decrease the concentration of
tacrolimus. Monitor and adjust dose.oTheoretical
▶Nevirapineis predicted to decrease the exposure totaxanes
(cabazitaxel). Avoid.rStudy
▶Nevirapineis predicted to decrease the concentration of
temsirolimus. Avoid.rTheoretical
▶Nevirapineis predicted to decrease the exposure toticagrelor.
oTheoretical
▶Nevirapineis predicted to decrease the exposure totofacitinib.
oStudy
▶Nevirapineis predicted to decrease the exposure totolvaptan.
oTheoretical
▶Nevirapinedecreases the efficacy ofulipristal. For FSRH
guidance, seeContraceptives, interactionsp. 497.r
Anecdotal
▶Nevirapineis predicted to decrease the exposure tovelpatasvir.
Avoid.oTheoretical
▶Nevirapineis predicted to decrease the exposure tovenetoclax.
Avoid.rStudy
▶Nevirapineis predicted to decrease the concentration of
voxilaprevir. Avoid.rTheoretical
▶Nevirapineis predicted to decrease the concentration of
zidovudine. Refer to specialist literature.rTheoretical
Nicardipine→see calcium channel blockers
Nicorandil→seeTABLE 8p. 848 (hypotension)
▶Aspirinis predicted to increase the risk of gastrointestinal
perforation when given withnicorandil.rTheoretical
▶Corticosteroidsincrease the risk of gastrointestinal
perforation when given withnicorandil.rAnecdotal
▶Nicorandilis predicted to increase the risk of gastrointestinal
perforation when given withNSAIDs.rTheoretical
▶Nicorandilis predicted to increase the risk of hypotension
when given withphosphodiesterase type-5 inhibitors. Avoid.
rTheoretical→Also seeTABLE 8p. 848
Nicotinic acid→seeTABLE 3p. 847 (anticoagulant effects)
▶Nicotinic acidis predicted to increase the risk of
rhabdomyolysis when given withstatins.rTheoretical
Nifedipine→see calcium channel blockers
Nilotinib→seeTABLE 15p. 850 (myelosuppression),TABLE 9p. 849 (QT-
interval prolongation)
▶Nilotinibis predicted to increase the exposure toaldosterone
antagonists(eplerenone). Adjusteplerenonedose.rStudy
▶Nilotinibis predicted to increase the exposure toalpha blockers
(tamsulosin).oTheoretical
▶Nilotinibis predicted to increase the exposure toalprazolam.
rStudy
▶Antacidsare predicted to decrease the absorption ofnilotinib.
Separate administration by at least 2 hours.o
Theoretical
▶Nilotinibis predicted to increase the exposure to
antiarrhythmics(propafenone). Monitor and adjust dose.
oStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to moderately decrease
the exposure tonilotinib. Avoid.rStudy
▶Antifungals, azoles(fluconazole, posaconazole)are predicted to
increase the exposure tonilotinib.oTheoretical→Also
seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to moderately increase the exposure tonilotinib.
Avoid.rStudy→Also seeTABLE 9p. 849
▶Nilotinibis predicted to increase the exposure to
antihistamines, non-sedating(mizolastine).rTheoretical
▶Nilotinibis predicted to increase the exposure to
antihistamines, non-sedating(rupatadine). Avoid.oStudy
▶Nilotinibis predicted to increase the concentration of
antimalarials(piperaquine).rTheoretical
▶Aprepitantis predicted to increase the exposure tonilotinib.
oTheoretical
▶Nilotinibis predicted to increase the exposure toaxitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Nilotinibis predicted to increase the exposure tobedaquiline.
Avoid prolonged use.nTheoretical→Also seeTABLE 9p. 849
▶Bosentanis predicted to decrease the exposure tonilotinib.
Avoid.rTheoretical
▶Nilotinibis predicted to increase the exposure tobosutinib.
Avoid or adjust dose.rTheoretical→Also seeTABLE 15
p. 850→Also seeTABLE 9p. 849
▶Nilotinibis predicted to increase the exposure tobuspirone.
Use with caution and adjust dose.oStudyBNFC 2018 – 2019 Nevirapine—Nilotinib 963
Interactions|Appendix 1A1